secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2022-01-13T23:59:59+00:00
Accession:  0001654954-22-000428
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata appoints Brittany Bradrick to Board and Audit Committee
---------------------------------------------------------------

- Board expanded from 7 to 8; Bradrick appointed as Class II director effective Jan 12, 2022.
- Bradrick brings over 25 years life science finance/strategy experience; currently CFO of Neurelis.
- Received option to purchase 10,000 shares at $1.50, vesting monthly over 12 months.
- Dr. Steven Mento steps down from Audit Committee but stays on Board and Nominating Committee.
- No family relationships or transactions requiring disclosure with other officers/directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495422000428/0001654954-22-000428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495422000428/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-000428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer